Premium
Stereochemical facets of clinical β‐blockers: An overview
Author(s) -
Vashistha Vinod Kumar,
Kumar Anuj
Publication year - 2020
Publication title -
chirality
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.43
H-Index - 77
eISSN - 1520-636X
pISSN - 0899-0042
DOI - 10.1002/chir.23200
Subject(s) - enantiomer , chemistry , chirality (physics) , pharmacology , pharmacodynamics , drug , stereochemistry , pharmacokinetics , chiral symmetry , medicine , physics , quantum mechanics , nambu–jona lasinio model , quark
The modern β‐adrenergic agonists (β‐blockers) possess one or more than one chiral center in their structure. Two enantiomers exhibit distinct pharmacodynamic and pharmacokinetic behaviors. Current progress in drug designing has resulted in the ability to understand the role of chirality in modern therapeutics. Furthermore, with a greater understanding of the molecular structure of precise drug targets, development of new drugs is directed towards the pure enantiomers instead of its racemates. The present review deals with a discussion on the stereochemical facets of chiral clinical β‐blockers. This review provides details of stereo‐selectivity in the pharmacological behavior of some of β‐blockers and their metabolites. An effort has been made on highlighting the distinction between the therapeutic behavior of the racemic mixtures and pure enantiomers.